GURUFOCUS.COM » STOCK LIST » Technology » Software » Advanced Health Intelligence Ltd (ASX:AHI) » Definitions » Debt-to-EBITDA

Advanced Health Intelligence (ASX:AHI) Debt-to-EBITDA : N/A (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Advanced Health Intelligence Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Advanced Health Intelligence's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$0.00 Mil. Advanced Health Intelligence's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was A$0.00 Mil. Advanced Health Intelligence's annualized EBITDA for the quarter that ended in Sep. 2023 was A$0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Advanced Health Intelligence's Debt-to-EBITDA or its related term are showing as below:

During the past 9 years, the highest Debt-to-EBITDA Ratio of Advanced Health Intelligence was -0.03. The lowest was -0.33. And the median was -0.16.

ASX:AHI's Debt-to-EBITDA is not ranked *
in the Software industry.
Industry Median: 1.005
* Ranked among companies with meaningful Debt-to-EBITDA only.

Advanced Health Intelligence Debt-to-EBITDA Historical Data

The historical data trend for Advanced Health Intelligence's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Health Intelligence Debt-to-EBITDA Chart

Advanced Health Intelligence Annual Data
Trend Apr15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.33 -0.25 -0.16 -0.06 -0.15

Advanced Health Intelligence Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Advanced Health Intelligence's Debt-to-EBITDA

For the Software - Application subindustry, Advanced Health Intelligence's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Health Intelligence's Debt-to-EBITDA Distribution in the Software Industry

For the Software industry and Technology sector, Advanced Health Intelligence's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Advanced Health Intelligence's Debt-to-EBITDA falls into.



Advanced Health Intelligence Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Advanced Health Intelligence's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.498 + 0.305) / -12.037
=-0.15

Advanced Health Intelligence's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Advanced Health Intelligence  (ASX:AHI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Advanced Health Intelligence Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Advanced Health Intelligence's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Health Intelligence (ASX:AHI) Business Description

Traded in Other Exchanges
Address
71-73 The Esplanade, Unit 5, South Perth, Perth, WA, AUS, 6151
Advanced Health Intelligence Ltd (AHI) is engaged in developing and delivering user-friendly biometric scans to render vital signs and health risk estimates to a smartphone. By leveraging the smartphone with purpose-built computer vision, machine learning models, and patented algorithms, AHI provides a private and secure way for individuals to perform biometric health-risk assessment and stratification. AHI's technology delivers simple-to-use, scalable, and cost-effective means to enable individuals to check, track and act towards better health outcomes. The combination of the patented and proprietary BodyScan dimensioning and composition capabilities and, FaceScan to return vital signs enables a unique health assessment capability made accessible anytime, anywhere through the smartphone.